AJ

Aquib Jawed

Active Director Director DIN 10051611
DIN 10051611 First appointment Feb 2023
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2023
Shareholding value •••• Premium profile

About Aquib Jawed

Data last updated:

Aquib Jawed is a Director at Caresfield Medicines Private Limited (since 2023). Caresfield Medicines Private Limited reported revenue of ₹41.7 Lakh (FY 2025).

DIN 10051611
Primary Designation Director
First Appointment 21 Feb 2023
Oldest Company Age 3 yrs
Largest company Caresfield Medicines Private Limited · ₹41.7 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Caresfield Medicines Private Limited U47721UP2023PTC177599
Director21 Feb 20232023₹41.7 Lakh (FY 2025)Active

Board colleagues of Aquib Jawed

Directorship timeline

Open interactive timeline →
Caresfield Medicines Private Limited
Premium access

Shareholding and investment profile for Aquib Jawed

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Aquib Jawed

Aquib Jawed currently holds 1 directorship: Caresfield Medicines Private Limited (Director, since 21 Feb 2023, revenue ₹41.7 Lakh (FY 2025)).

Aquib Jawed was first appointed on 21 Feb 2023 as Director at Caresfield Medicines Private Limited.

The current boards of Aquib Jawed's companies include Arvind Singh (Caresfield Medicines Private Limited), Rifat Praveen (Caresfield Medicines Private Limited), Shalini Singh (Caresfield Medicines Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available